BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 10633042)

  • 1. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
    Neumeyer JL; Bidlack JM; Zong R; Bakthavachalam V; Gao P; Cohen DJ; Negus SS; Mello NK
    J Med Chem; 2000 Jan; 43(1):114-22. PubMed ID: 10633042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse.
    Neumeyer JL; Mello NK; Negus SS; Bidlack JM
    Pharm Acta Helv; 2000 Mar; 74(2-3):337-44. PubMed ID: 10812979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
    Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
    Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.
    Neumeyer JL; Gu XH; van Vliet LA; DeNunzio NJ; Rusovici DE; Cohen DJ; Negus SS; Mello NK; Bidlack JM
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2735-40. PubMed ID: 11591513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties.
    Mathews JL; Fulton BS; Negus SS; Neumeyer JL; Bidlack JM
    Neurochem Res; 2008 Oct; 33(10):2142-50. PubMed ID: 18528756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
    Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
    J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 8-Carboxamidocyclazocine: a long-acting, novel benzomorphan.
    Bidlack JM; Cohen DJ; McLaughlin JP; Lou R; Ye Y; Wentland MP
    J Pharmacol Exp Ther; 2002 Jul; 302(1):374-80. PubMed ID: 12065740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-affinity carbamate analogues of morphinan at opioid receptors.
    Peng X; Knapp BI; Bidlack JM; Neumeyer JL
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1508-11. PubMed ID: 17276685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and in vitro and in vivo activity of (-)-(1R,5R,9R)- and (+)-(1S,5S,9S)-N-alkenyl-, -N-alkynyl-, and -N-cyanoalkyl-5, 9-dimethyl-2'-hydroxy-6,7-benzomorphan homologues.
    May EL; Jacobson AE; Mattson MV; Traynor JR; Woods JH; Harris LS; Bowman ER; Aceto MD
    J Med Chem; 2000 Dec; 43(26):5030-6. PubMed ID: 11150174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
    Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
    Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
    Neumeyer JL; Zhang A; Xiong W; Gu XH; Hilbert JE; Knapp BI; Negus SS; Mello NK; Bidlack JM
    J Med Chem; 2003 Nov; 46(24):5162-70. PubMed ID: 14613319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
    McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.
    Ananthan S; Khare NK; Saini SK; Davis P; Dersch CM; Porreca F; Rothman RB
    Bioorg Med Chem; 2003 Sep; 11(18):4143-54. PubMed ID: 12927876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
    Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
    Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of the binding of [3H]bremazocine in guinea-pig brain: evidence for multiplicity of the kappa-opioid receptors.
    Tiberi M; Magnan J
    Can J Physiol Pharmacol; 1989 Oct; 67(10):1336-44. PubMed ID: 2558788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
    Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence.
    Bidlack JM
    Adv Pharmacol; 2014; 69():387-418. PubMed ID: 24484983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.